Journal
SURFACES
Volume 5, Issue 1, Pages 187-201Publisher
MDPI
DOI: 10.3390/surfaces5010012
Keywords
electrochemical biosensor; SARS-CoV-2; COVID-19 antibodies; laser-induced graphene
Funding
- CNPq [PCI/302214/2021-6]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superio-Brasil [001]
- CAPES-PrInt (SWE) [88887.310585/2018-00, 88887.370699/2019-00]
- FAPERGS 06/2020-Ciencia e Tecnologia no Combate a COVID-19 [20/2551-00002608]
- Forensic National Institute of Science and Technology [465450/2014-8]
- UFABC EDITAL 73/2020 [23006.002353/2020-41]
Ask authors/readers for more resources
A diagnostic chip platform based on a disposable electrochemical biosensor has been developed for the detection of SARS-CoV-2 antibodies. It helps with epidemiological public safety measures and the control of population's immune response to vaccines.
The severe acute respiratory syndrome originated by the new coronavirus (SARS-CoV-2) that emerged in late 2019, known to be a highly transmissible and pathogenic disease, has caused the COVID-19 global pandemic outbreak. Thus, diagnostic devices that help epidemiological public safety measures to reduce undetected cases and isolation of infected patients, in addition to significantly help to control the population's immune response to vaccine, are required. To address the negative issues of clinical research, we developed a Diagnostic on a Chip platform based on a disposable electrochemical biosensor containing laser-induced graphene and a protein (SARS-CoV-2 specific antigen) for the detection of SARS-CoV-2 antibodies. The biosensors were produced via direct laser writing using a CO2 infrared laser cutting machine on commercial polyimide sheets. The presence of specific antibodies reacting with the protein and the K-3[Fe(CN)(6)] redox indicator produced characteristic and concentration-dependent electrochemical signals, with mean current values of 9.6757 and 8.1812 mu A for reactive and non-reactive samples, respectively, proving the effectiveness of testing in clinical samples of serum from patients. Thus, the platform is being expanded to be measured in a portable microcontrolled potentiostat to be applied as a fast and reliable monitoring and mapping tool, aiming to assess the vaccinal immune response of the population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available